Just how much vaccine money is on the table? To view this email as a web page,
click here Moderna blueprints plant upgrades to rev up vaccine supply to 3B doses a year Seniors fully vaccinated by Pfizer, Moderna shots 94% less likely to be hospitalized for COVID-19: CDC Just how much COVID-19 vaccine money is on the table? A whopping $157B through 2025, report says LabCorp, still riding the COVID-19 testing wave, exceeds its own expectations with $4.2B Q1 revenue Brii's COVID antibody combo cleared for phase 3 as it targets high-risk patients to head off hospitalization UPDATED Coronavirus tracker: U.S. at a 'crossroads' in race between COVID-19 virus and vaccines, Fauci says COVID-19 tracker: Lilly's arthritis drug wins quick EMA review; Teva's vaccine production offers rebuffed CHS posts $68M loss in Q1 amid a 14% decline in admissions due to pandemic Featured Story | By Fraiser Kansteiner Moderna is socking cash into its manufacturing facilities and those of its contract manufacturing partners in Europe, in a move that could lift the biotech's COVID-19 vaccine supply to a whopping 3 billion doses next year. read more |
| |
|---|
|
Top Stories By Dave Muoio The first real-world evidence of these vaccines' effectiveness among U.S. seniors promises relief to flagging providers and bolsters the case public health officials are making to hesitant Americans. read more By Kevin Dunleavy In its annual projections for global drug sales, the IQVIA Institute for Human Data Science estimates that spending on COVID-19 vaccines will reach $157 billion by the end of 2025. read more By Andrea Park The vast majority of the quarter’s revenues across LabCorp's entire business were driven by organic growth, one-third of which came from COVID testing alone. read more By Annalee Armstrong Brii Biosciences has been given the green light to proceed with a phase 3 trial for a COVID-19 combination therapy in ambulatory care patients after the National Institutes of Health shut down a study of hospitalized patients in March. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Europe's drug regulator said Eli Lilly's rheumatoid arthritis drug Olumiant, also known as baricitinib, would get an accelerated review for emergency use in COVID-19 patients. No company has taken up Teva's offer to help make COVID-19 vaccines, the company's CEO says. And more headlines read more By Robert King Community Health Systems posted a net loss of $64 million after major declines in patient admissions in the first quarter of the year. read more |
|
